In a research report released this morning, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Insmed Incorporated (NASDAQ:INSM) with a $51 price …
Piper Jaffray analyst Joshua Schimmer came out with a research note on Nektar Therapeutics (NASDAQ:NKTR), following the company’s fourth-quarter results posting revenue of $19.5 million compared to Jaffray’s estimate …
In a research report published Wednesday, Piper Jaffray analyst Joshua Schimmer reiterated a Neutral rating on MannKind Corporation (NASDAQ:MNKD) with a $7 price target, following …
Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in today with a few insights on Pharmacyclics, Inc. (NASDAQ:PCYC), following the release of the company’s fourth-quarter results, posting GAAP net …
In a research report sent to investors today, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Gilead Sciences (NASDAQ:GILD) with a …
Piper Jaffray’s healthcare analyst Joshua Schimmer is weighing in on Gilead Sciences’ (NASDAQ:GILD), after the company reported a solid fourth-quarter performance led by the HCV franchise, but conservatively guided below …
In a research report published Wednesday, Piper Jaffray analyst Joshua Schimmer downgraded shares of Isis Pharmaceuticals (NASDAQ:ISIS) to Neutral, and reduced the price target to …
Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in with an update on Celgene Corporation (NASDAQ:CELG), as the company reported yesterday morning full fourth-quarter results and guidance. The analyst …
In a research note issued today, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Biogen (NASDAQ:BIIB) with a $386 price target, following last …
Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in today with his thoughts on Biogen Idec (NASDAQ:BIIB), following the results from a phase 2 study of …
